Clinitech Laboratory Ltd Directors Report

To,

The Members,

Clinitech Laboratory Limited

(formerly Known as Clinitech Laboratory Private Limited)

Your Directors have pleasure in presenting their 15^thAnnual Report on the Standalone Audited Financial Statements of Clinitech Laboratory Limited (formerly Known as Clinitech Laboratory Private Limited)("the Company") for the Financial Year ended March 31, 2025.

1. Financial Summary:

The summarized financial performance of the Company for the FY2024-25 and 2023-24are given below:

[Amount in lacs.]

Particulars	Standalone
	2024-25	2023-24
Revenue from operations	823.49	640.30
Other Income	22.78	3.62
Total Revenue	846.27	643.92
Total Expenses	790.80	593.40
Profit/(Loss) before exceptional items and tax	55.47	50.52
Exceptional Items/prior period item	-	-
Net Profit Before Tax	55.47	50.52
Provision for Tax
- Current Tax	15.95	14.36
- Deferred Tax (Liability)/Assets	0.04	(0.96)
- Tax Adjustments	0.00	0.00
Net Profit/(Loss) After Tax	39.47	37.12
Earnings per equity share (for continuing operation):
- Basic	1.90	2.37
- Diluted	1.90	2.37

2. Review of Operations:

During the financial year under review, the Company has posted total revenue of INR 846.27 lakhs as against INR 643.92 lakhs for the corresponding previous year.

Further, the Company earned net profit after tax of INR 39.47 lakhs as against net profit after tax INR 37.12 lakhs for the corresponding previous year.

3. State of Affairs and Future Outlook:

Your Board is exploring new avenues to engage Company into activities pertaining to pathological laboratory testing services, with an expectation to grow its business in upcoming year under the

"healthcare service" sector. The company has witnessed upward trend in its revenues and Net profits as compared to previous financial year. The company is hopeful to do better in upcoming future.

The Company was incorporated as Clinitech Laboratory Private Limited on March 19, 2010. Further, the company was converted to Public Limited on August 25, 2023. The Company has pursuant to Section 23, 26, 179(3), 62(1)(c) &all other applicable provisions of Companies Act, 2013 and SEBI (ICDR) Regulations, 2018 carried out the procedure of Initial Public Offering of Equity shares of the Company. The Company listed its Equity shares on BSE Limited (BSE), SME platform with effect from August 01, 2024.

In the coming years the company shall focus on delivering the quality products and explore more avenues in the "healthcare service" sector and focus on the future development and success of the company. We shall together work towards strengthening the core competencies of the company and strive to increase the revenue from operation and consequently increase the net profit of the company in the future. We are hopeful of growing in the healthcare service sector and increase profits in the near future.

4. Material changes and commitments affecting the financial position of the Company:

4.1 Initial Public Offer ("IPO") and Listing

During the financial year, the Company has pursuant to Section 23, 26, 179(3), 62(1)(c) &all other applicable provisions of Companies Act, 2013 and SEBI (ICDR) Regulations, 2018 carried out the procedure of Initial Public Offering of Equity shares of the Company. The Company listed its Equity shares on BSE Limited (BSE), SME platform with effect from August 01, 2024 in accordance with the listing and trading approval dated July 30, 2024 and allotted 6,02,400 Equity shares on July 30, 2024 issued through Initial Public Offer (IPO).

4.2 Change in status of the company (Unlisted to Listed)

As the company is listed on BSE limited at SME platform and hence the Corporate Identity Number

("CIN") of the company was changed from U85195MH2010PLC201078 to L85195MH2010PLC201078

5. Dividend:

In order to conserve the resources for the further growth of the Company, your Directors think fit not to recommend any dividend for the financial year 2024-25.

6. Transfer to Reserves:

The Board of Directors have not transferred any amounts in General reserve account.

7. Share Capital:

7.1 Authorized Share Capital

As on March 31, 2025, the authorized capital of the company is INR 5,00,00,000/- (Indian Rupees Five Crore only) divided into 50,00,000 (Fifty Lakhs) Equity Shares of INR 10/- (Indian Rupees Ten Only) each.

7.2 Changes in Issued, Subscribed and Paid-up Share Capital:

As on March 31, 2024, the issued, subscribed and paid-up share capital of the company was INR 1,68,00,000/- (Indian Rupees One Crore Sixty Eight Lakhs only) divided into 16,80,000 (Sixteen Lakhs Eighty Thousand) Equity Shares of INR 10/- (Indian Rupees Ten Only) each. During the financial year, 6,02,400 Equity shares were allotted through Initial Public Offer on July 30, 2024 thereby increasing the issued, subscribed and paid-up share capital of the company to INR 2,28,24,000/- (Indian Rupees Two Crores Twenty Eight Lakh Twenty Four Thousand only) divided into 22,82,400 (Twenty Two Lakh Eighty Two Thousand Four Hundred) Equity Shares of INR 10/- (Indian Rupees Ten Only) each.

The Company listed its 22,82,400 Equity shares on SME platform of BSE Limited("BSE") on August 01, 2024.

Consequently the issued, subscribed and paid-up share capital of the company as on March 31, 2025 is INR 2,28,24,000/- (Indian Rupees Two Crores Twenty Eight Lakh Twenty Four Thousand only) divided into 22,82,400 (Twenty Two Lakh Eighty Two Thousand Four Hundred) Equity Shares of INR 10/- (Indian Rupees Ten Only) each.

8. Management Discussion and Analysis:

The Management Discussion and Analysis as required in terms of the Listing Regulations is annexed to the report as Annexure I and is incorporated herein by reference and forms an integral part of this report.

9. Board of Directors:

Your Board of Directors consist of eminent professionals with considerable integrity, experience and expertise (including the proficiency) of the independent director which contribute to overall Board effectiveness.

As on March 31, 2025, the Board of your company consists of 6 (Six) Directors, out of which 2 (Two) are Executive Directors and 4 (Four) are Non-Executive Directors [which includes One Non-Executive Non-Independent and Two Independent Directors]. The composition of Board is in accordance with the provisions of Section 149 of the Companies Act, 2013 and Regulation 17 of SEBI (LODR) Regulations, 2015.

9.1 Inductions/Appointment/Re-appointment/Resignation of Director:

Pursuant to section 152(6) of the Companies Act, 2013 and in terms of Articles of Association of the Company, Mr. Jagdish Umakant Nayak (DIN: 00646672), Director of the Company, retires by rotation and being eligible; offers himself for re-appointment at the forthcoming 15^thAnnual General

Meeting. The Board recommends the said reappointment for shareholders approval.

During the financial year, there were no changes in composition of Board of Directors of the Company.

All the directors of the Company have confirmed that they satisfy the fit and proper criteria as prescribed under the applicable regulations and that they are not disqualified from being appointed as directors in terms of Section 164(2) of the Companies Act, 2013.

10. Declaration by Independent Directors:

The Independent Director(s) have submitted their disclosure to the Board that they fulfill all the requirements as to qualify for their appointment as Independent Director, under the provisions of section 149 of the Companies Act, 2013 as well as Regulation 17 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

11. Key Managerial Personnel:

Pursuant to Section 203 of the Companies Act, 2013, the Key Managerial Personnel of the Company as on March 31, 2025 are:

Sr. No. Name of KMP	Designation
1. Ms. Jagdish Umakant Nayak	Managing Director
2. Mr. Jyoti Jagdish Nayak	Whole-time Director
3. Mr. Rahul Motilal Patil	Chief Financial Officer
4. *Mr. Bharat Kumar Bohra	Company Secretary &Compliance Officer

*As on report date, Mr. Bharat Kumar Bohra has resigned from the position of Company Secretary & Compliance Officer w.e.f June 02, 2025 and Ms. Shruti Hemant Patankar (Mem. No. A76156) was appointed for the said position w.e.f June 06, 2025.

12. Board Meetings:

Dates for Board Meetings are well decided in advance and communicated to the Board and the intervening gap between the meetings was within the period prescribed under the Companies Act, 2013 and the Listing Agreement. The agenda and explanatory notes are sent to the Board in advance or with the permission of the Board at shorter notice. The Board periodically reviews compliance reports of all laws applicable to the Company. The Board usually meets once in every quarter to review the progress of business and transact other items listed as agendas. Additional meetings are held, when necessary.

During the financial year ended March 31, 2025, 09 (Nine) Board Meetings were held, the dates of which are as follows:

Sr. No.	Date of Meeting	No. of Director entitled to attend	No. of Director attended
1	12/04/2024	6	6
2	24/06/2024	6	6
3	05/07/2024	6	6
4	30/07/2024	6	6
5	12/08/2024	6	6
6	24/10/2024	6	6
7	13/11/2024	6	5
8	25/02/2025	6	6
9	25/03/2025	6	6

Attendance details of Directors for the year ended March 31, 2025 are given below:

Name of the Directors	Category	No. of Board Meetings attended
Jagdish Umakant Nayak	Managing Director	9
Jyoti Jagdish Nayak	Whole time Director	9
Ashutosh Jagdish Nayak	Non-Executive Director	9
Ravikant Moreshwar Mhatre	Independent Director	9
Smita Arjun Patil	Independent Director	9
Balu Laxman Kumbharkar	Independent Director	8

The gap between any two Board meetings during this period did not exceed one hundred and twenty days in accordance with the provisions of the Companies Act, 2013.

CLINITECH LABORATORY LIMITED ANNUAL REPORT 2024-25

13. Separate Meeting of Independent Directors- Board Evaluation &Discussions with

Independent Directors:

Pursuant to paragraph VII of Schedule IV, in terms of Section149 (8) of Companies Act, 2013 and Regulation 25 (3) & (4) of Securities and Exchange Board of India (Listing Obligations and

Disclosure requirements, 2015, the Boards policy is to regularly have separate meetings with

Independent Directors, to update them on all business related issues, new initiatives, changes in the industry specific market scenario, review quality, quantity, and timeliness of the flow of information between the Management and the Board and evaluate performance of Non-independent Directors, Chairperson of the company and Board as a whole. The Code for Independent Director is available on the website of the company atwww.ctllab.in.

The Meeting of Independent Directors of the Company was held on March 25, 2025.All the independent directors were present at this meeting.

13.1 Familiarization Programme:

Pursuant to the SEBI Listing Regulations, the Company has developed a Familiarization Programme for the Independent Directors, with a view to familiarize them with their role, rights, and responsibilities in the Company, the nature of the industry in which the Company operates, its business plans, business model, corporate strategy, services, the governance structure, policies, processes etc. Details of the Familiarization Programme of Independent Directors of the Company are available on the website of the Company atwww.ctllab.in.

14. Board Evaluation:

Pursuant to the provisions of the Companies Act, 2013 and the Listing Agreement/ SEBI (LODR) Regulations, 2015, the Board is required to carry out an annual performance evaluation of its own performance, the directors individually as well as the evaluation of the working of its Committees. The policy related with code of conduct for Board of Directors and senior management is available on the website of the company at www.ctllab.in.

15. Formation of Committee of Board:

15.1 Audit Committee:

Your Company has formed an Audit Committee as per the provisions of Section 177 of the Companies Act, 2013 and Regulation 18 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is functional as per the aforementioned provisions. All members of the Audit Committee possess strong knowledge of accounting and financial management.

The primary objective of the Audit Committee is to monitor and provide an effective supervision of the Managements financial reporting process, to ensure accurate and timely disclosures, with the highest levels of transparency, integrity and quality of financial reporting. The Committee oversees the work carried out in the financial reporting process by the Management, the statutory auditor and notes the processes and safeguards employed by each of them.

During the financial year ended March 31, 2025, 04 (Four) meetings of committee were held, the dates of which are as follows:

Sr. No.	Date of Meeting	No. of Director entitled to attend	No. of Director attended
1	24/06/2024	3	3
2	05/07/2024	3	3
3	13/11/2024	3	3
4	25/03/2025	3	3

Details of the composition of the Committee and attendance during the financial year are as under:

Sr. No.	Name of Directors	Designation	No. of Meetings Attended
1.	Mr. Ravikant	Chairman, Independent Director	4
	Moreshwar Mhatre
2.	Ms. Smita Arjun Patil	Member, Independent Director	4
3.	Mr. Balu Laxman	Member, Independent Director	4
	Kumbharkar

15.2 Nomination & Remuneration Committee:

The Board of Directors has framed a policy which lays down a framework in relation to remuneration of Directors. This policy also lays down criteria for selection and appointment of Board Members. The Board of Directors is authorized to decide Remuneration to Executive Directors. The Remuneration structure comprises of Salary and Perquisites. Salary is paid to Executive Directors within the Salary grade approved by the Members. The Nomination & Remuneration committee has been assigned to approve and settle the remuneration package with optimum blending of monetary and non-monetary outlay.

During the financial year ended March 31, 2025, 01 (One) meetings of committee was held on March 25, 2025.

Details of the composition of the Committee and attendance during the financial year are as under:

Sr. Name of Directors Designation	No. of	No. of
No.	Committee meetings entitled to attend	Meetings Attended
1. Mr. Balu Laxman Chairman, Independent Director	1	1
Kumbharkar
2. Mr. Ravikant Member, Independent Director	1	1
Moreshwar Mhatre
3. Ms. Smita Arjun Patil Member, Independent Director	1	1

15.2.1 Nomination & Remuneration Policy:

In terms of requirements prescribed under Section 178(3) of the Companies Act, 2013, the Nomination and Remuneration Policy inter-alia providing the terms for appointment and payment of remuneration to Directors and Key Managerial Personnel.

The said policy is annexed to this report as Annexure II and is also available on our website www.ctllab.in.

During the financial year, the details of remuneration paid to Directors and Key Managerial Personnel are as under:

Sr.No. Name of Directors and KMP	Designation	Remuneration per annum (In INR)
1. Mr. Jagdish Umakant Nayak	Managing Director	24,00,000/-
2. Mrs. Jyoti Jagdish Nayak	Whole time Director	24,00,000/-
3. Mr. Rahul Motilal Patil	Chief Financial Officer	7,20,500/-
4. *Mr. Bharat Kumar Bohra	Company Secretary	3,60,000/-

*As on report date, Mr. Bharat Kumar Bohra has resigned from the position of Company Secretary & Compliance Officer w.e.f June 02, 2025

15.3 Stakeholders Relationship Committee:

The terms of reference are in line with Section 178 of the Companies Act, 2013 and Regulation 20 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)

Regulations, 2015. The Committee reviews Shareholders/ Investor s complaints like non-receipt of Annual Report, physical transfer/ transmission/transposition, split/ consolidation of share certificates, issue of duplicate share certificates etc. This Committee is also empowered to consider and resolve the grievance of other stakeholders of the Company including security holders.

During the financial year ended March 31, 2025, 01 (One) meeting of committee was held on March 25, 2025.

Details of the composition of the Committee and attendance during the year are as under:

Sr. No.	Name of Directors	Designation	No. of Committee meetings entitled to attend	No. of Meetings Attended
1.	Ms. Smita Arjun Patil	Chairman, Independent Director	1	1
2.	Mr. Balu Laxman	Member, Independent Director	1	1
	Kumbharkar
3.	Mr. Ravikant	Member, Independent Director	1	1
	Moreshwar Mhatre
4.	Mr. Jagdish Umakant	Member, Managing Director	1	1
	Nayak

The details of complaints received and resolved during the Financial Year ended March 31, 2025 are given in the Table below. The complaints relate to non-receipt of annual report, dividend, share transfers, other investor grievances, etc.

Details of complaints received and resolved during the Financial Year 2024-25:

Particulars	Number of Complaint
Opening as on April 1, 2024	Nil
Received during the year	Nil
Resolved during the year	Nil
Closing as on March 31, 2025	Nil

16. Directors Responsibility Statement:

Pursuant to Section 134(3)(c) & 134(5) of the Companies Act, 2013, the Board of Directors of the Company hereby confirm that:

(a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;

(b) the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors have prepared the annual accounts on a going concern basis;

(e) the directors have laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

(f) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

17. Particulars of Employees and Related Disclosures

The information required pursuant to Section 197 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Amendment Rules, 2016 in respect of employees of the Companyis enclosed as Annexure III and forms an integral part of this report.

Further, as per the provisions specified in Rule 5 of Companies (Appointment & Remuneration of Managerial Personnel) Amendment Rules, 2016, none of the employees of the Company are in receipt of remuneration exceeding Rs. 1,02,00,000/- per annum, if employed for whole of the year or Rs. 8,50,000/- per month if employed for part of the year.

Further, the name of top ten employees in terms of remuneration drawn is disclosed in Annexure IV and forms an integral part of this report.

18. Annual Return:

Pursuant to Notification dated 28th August, 2020 issued by the Ministry of Corporate Affairs as published in the Gazette of India on 28^thAugust, 2020, the details forming part of the extract of Annual Return in Form MGT-9 is not required to be annexed herewith to this report. However, the Annual Return in Form MGT-7 as required under Section 92(3) read with Section 134(3)(a) of the Act and the Companies (Management and Administration) Rules, 2014will be made available on the website of the Company at: www.ctllab.in.

19. Details of Subsidiary/Joint Ventures/Associate Companies:

The company does not have any Subsidiary/Joint Ventures/Associate Companies as on March 31, 2025, therefore there is nothing to report on this behalf.

20. Statutory Auditors and Auditors Report:

At the 14^th Annual General Meeting held on July 11, 2024, M/s. Kale Malde & CO., Mumbai (Firm Registration Number 154422W) Chartered Accountant, were appointed as Statutory Auditor of the Company to hold the office for the period of five years i.e. from the conclusion of 14^thAnnual General Meeting till the conclusion of the 19^th Annual General Meeting, to be held for the FY 2028-29.

Explanation(s)/ Comment(s) Pursuant To Section 134(3)(f)(i), If Any, of The Companies Act, 2013:

There are no adverse remarks/Qualifications made in Statutory Report issued by M/s. Kale Malde & CO., Chartered Accountant, Statutory Auditor of the Company.

Auditors Report is self explanatory and need not call for any explanation by your Board.

21. Secretarial Audit:

In terms of Section 204 of the Act and Rules made thereunder, M/s. Deep Shukla & Associates, Practicing Company Secretaries, have been appointed as Secretarial Auditors of the Company vide Board approval dated March 25, 2025 for a term of 5 (five) financial years from FY 2024-25 to FY 2028-29.

The Secretarial Audit Report is enclosed as Annexure V to this report.

22. Internal Audit & Controls:

Pursuant to the provisions of Section 138 of the Companies Act, 2013 and the Companies (Accounts) Rules, 2014, M/s. Kalpesh Khatri & Associates, Chartered Accountants (Firm Regn No.: 0139570W) were appointed as an Internal Auditor of the Company for a term of 5 (five) years i.e. from FY 2024-25 to FY 2028-29, to issue the report for respective financial years.

The Company has in place adequate internal financial controls with reference to the financial statement. The Audit Committee of the Board periodically reviews the internal control systems with the management and Statutory Auditors.

23. Employees Stock Option Plan:

The Company has not provided stock options to any employee during the financial year.

24. Vigil Mechanism:

Pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, a Vigil Mechanism for directors and employees to report genuine concerns has been established. The Vigil Mechanism Policy has been uploaded on the website of the Company at www.ctllab.in.The employees of the Company are made aware of the said policy at the time of joining the Company.

During the financial year, no complaints were received by the Company.

25. Risk Management Policy:

The Company has laid down the procedure to inform the Board about the risk assessment and minimization procedures. These procedures are reviewed by the Board annually to ensure that there is timely identification and assessment of risks, measures to mitigate them, and mechanisms for their proper and timely monitoring and reporting.

The Company does not fall under the ambit of top 500 listed entities, determined on the basis of market capitalization as at the end of the immediately preceding financial year. Hence, compliance under Regulation 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable.

26. Code for Prohibition of Insider Trading:

Your Company has adopted the Internal Code of conduct for Regulating, monitoring and reporting of trades by Designated persons under the Securities and Exchange Board of India (Prohibition of

Insider Trading) Regulation, 2015 ("Code") for prohibition of insider trading in the securities of the CTLLAB to curb the practice for dealing in the securities while having Unpublished Price Sensitive

Information ("UPSI") by the Insiders of the Company.

The Code, inter alia, prohibits dealing in securities by insiders while in possession of unpublished price sensitive information. The said Code has been amended, from time to time, to give effect to the various notifications/circulars of Securities and Exchange Board of India ("SEBI") with respect to the

SEBI (Prohibition of Insider Trading) Regulations, 2015.

Your Company has also formulated and adopted the Policy and Procedures for inquiry in case of leak or suspected leak of Unpublished Price Sensitive Information [Under Regulation 9A (5) of Securities and Exchange Board of India (Prevention of Insider Trading) Regulations, 2015]. The Policy of Insider trading has been uploaded on website of the company at www.ctllab.in.

27. Corporate Governance Report:

Your Company is committed to achieving and adhering to the highest standards of Corporate Governance, however the provisions of the Corporate Governance is not applicable to the Company pursuant to regulation 15(2)(a) of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

34

28. Deposits:

The Company has neither accepted nor renewed any fixed deposits during the year under Section 76 of the Companies Act, 2013. There are no unclaimed deposits, unclaimed / unpaid interest, refunds due to the deposit holders or to be deposited to the Investor Education and Protection Fund as on March 31, 2025.

29. Loans & Guarantees:

During the financial year, the Company has not provided any loan, guarantee, security covered under the provisions of Section 186 of the Companies Act, 2013, to any person or other body corporate.

30. Related Party Transactions:

Related party transactions, if any, that were entered into during the period ended March 31, 2025, were on an arms length basis and were in the ordinary course of business. There are no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large.

None of the Directors has any pecuniary relationships or transactions vis-?-vis the Company.

Further all the necessary details of transaction entered with the related parties pursuant to provisions of Section 188(1) of the Companies Act, 2013 are attached herewith in Form AOC-2 for your kind perusal and information as Annexure VI

The details of the other related party transactions as per Indian Accounting Standard 24 are also set out in Note No. 27 to the Significant Accounting policies part of this report.

31. Conservation of Energy, Research and Development, Technology Absorption and Foreign

Exchange:

The details of conservation of energy, technology absorption, foreign exchange earnings and outgo are as follows:

30.1 Conservation of Energy:

The use of energy is being optimized through improved operational methods. Continuous efforts are being made to optimize and conserve energy by improvement in production process. Even though its operations are not energy intensive, significant measures are taken to reduce energy consumption by using energy efficient equipment. The Company regularly reviews power consumption patterns in its all locations and implements requisite improvements/changes in the process in order to optimize energy/ power consumption and thereby achieve cost savings.

Steps taken for utilizing alternate sources of energy-

The Company has not made any investment for utilizing alternate source of energy.

Capital investment on energy conservation equipment-

The Company has taken adequate measures to conserve energy by way of optimizing usage of power.

30.2 Absorption of Technology:

I. The efforts made towards technology absorption:

The Company values innovation and applies it to every facet of its business. This drives development of distinctive new products, ever improving quality standards and more efficient processes.

The Company has augmented its revenues and per unit price realization by deploying innovative marketing strategies and offering exciting new products. The depth of designing capabilities was the core to our success over the years.

II. Benefits derived as a result of the above efforts:

As a result of the above, the following benefits have been achieved:

a) Better efficiency in operations, b) Greater precision, c) Retention of existing customers and expansion of customer base, d) Lower inventory stocks resulting in low carrying costs.

III. The Company has not imported any technology during the year under review;

IV. The Company has not expended any expenditure towards Research and Development during the year under review.

30.3 Foreign Exchange Earnings and Outgo:

During the financial year, there was no earning and outgoing in foreign exchange.

32. Corporate Social Responsibility:

The Company is committed to discharging its social responsibility as a good corporate citizen.

During the financial year, the Company has not expended any amount towards CSR activities as the same is not applicable to the Company for the FY 2023-24 pursuant to section 135 of the Companies Act, 2013. Consequently, the company is not required to adopt any policy and formulate CSR Committee.

33. Cost Record & Cost Audit:

Pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013, read with the Companies (Audit and Auditors) Rules, 2014 and the Companies (Cost Records and Audit) Rules, 2014, Maintenance of Cost Record and conducting Cost Audit is not applicable to our Company.

34. Obligation of Company under the Sexual Harassment of Women at Workplace

(Prevention, Prohibition and Redressal) Act, 2013:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment at workplace (Prevention, prohibition and Redressal) Act, 2013.The Company has an Internal Complaints Committee, providing a redressal mechanism. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

During the year ended 31^st March 2025, the status of complaints is as follows:

Number of compliant as on 01st April, 2024	NIL
Number of complaints received during the	NIL
year
Number of complaints resolved during the	NIL
year
Number of complaints pending as on 31st	NIL
March, 2025

35. Obligation of Company under the Maternity Benefit Act, 1961 :

The Company complies with the provisions of the Maternity Benefit Act, 1961 and the HR department of the company is responsible for the same. All permanent women employees (except contractual, temporary, trainees) are covered under this system.

36. Secretarial Standards:

The Company has in place proper systems to ensure compliance with the provisions of the applicable secretarial standards issued by The Institute of Company Secretaries of India and such systems are adequate and operating effectively.

37. Significant and Material Orders passed by the Regulators or Courts or Tribunals:

There are no significant and material orders passed by the Regulators / Courts / Tribunals which would impact the going concern status of the Company and its future operations.

38. Listing on stock exchange

The shares of the Company were listed on BSE Limited on Small, Medium Enterprise Platform

("SME Platform") on Thursday, August 01, 2024.

39. Other Disclosure:

? There was no change in the nature of the business or any activity of business of your Company; ? Your Company has not accepted/invited deposits from the public falling within the ambit of Section 73 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 and has not taken any loan from the Promoters or Directors; ? There were no proceedings, filed by your Company or filed against the Company, pending under the Insolvency and Bankruptcy Code, 2016 as amended, before the National Company Law Tribunal or other Courts as on March 31, 2025. ? Your Company has not issued shares with differential voting rights and sweat equity shares during the year under review. ? There were no instances where your Company required the valuation for one time settlement or while taking the loan from the Banks or Financial institutions during the financial year.

40. Acknowledgement:

The Directors would like to thank all shareholders, customers, bankers, suppliers and everybody else with whose help, cooperation and hard work the Company is able to achieve the results. The Directors would also like to place on record their appreciation of the dedicated efforts put in by the employees of the Company.

	For & on behalf of the Board of Directors of
	Clinitech Laboratory Limited
	(formerly known as Clinitech Laboratory Private Limited)
	Sd/-	Sd/-
	Jagdish Umakant Nayak	Jyoti Jagdish Nayak
	Managing Director	Whole-time Director
	DIN: 00646672	DIN: 02945625
Place: Navi Mumbai
Date: August 19, 2025
Registered office address:
AL-1/545, Sector 16, Airoli,
Opposite Radhikabai Meghe Vidyalaya,
Thane-400708, Navi Mumbai, Maharashtra, India.